Suzhou, China – From March 22 to March 25, MicroPort^® Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort^® CardioFlow"), a wholly owned subsidiary of Shanghai MicroPort^® Medical (Group) Co., Ltd. ("MicroPort^®"), attended CIT 2018 and released the one-year clinical outcome of VitaFlow^® Transcatheter Aortic Valve and Delivery System ("VitaFlow^®").

Shanghai, China – On August 22, MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort^®CardioFlow"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort^®"), entered into financing agreements at a consideration of RMB430million and achieved a valuation of RMB2.1 billion after this round of financing.

Shanghai, China - MicroPort^® CardioFlow has recently completed the patient enrollment of the pre-market clinical trial of its self-developed VitaFlow^® Transcatheter Aortic Valve and Delivery System ("VitaFlow^®"), which is three months prior to the scheduled completion date. The clinical trial is a prospective, multi-center trial, aiming at assessing the safety and efficacyof VitaFlow^® in the treatment of severe aortic stenosis. The clinical trial was organized by Professor Junbo Ge, an academician of Chinese Society of Sciences and a renowned cardiologist. Zhongshan Hospital of Fudan University, led eleven domestic hospitals to complete the clinical trial.